Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991547 | 1.00 | GRM5 (0.76) | GRM5NPC1MAPTRAB9AHPGD | |
| SCHEMBL990217 | 0.90 | GRM5 (0.71) | GRM5HPGD | |
| SCHEMBL990274 | 0.90 | GRM5 (0.71) | GRM5HPGD | |
| SCHEMBL991034 | 0.88 | GRM5 (0.81) | GRM5HPGD | |
| SCHEMBL991073 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL990783 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL3415829 | 0.85 | GRM5 (0.77) | GRM5HPGD | |
| SCHEMBL992205 | 0.85 | GRM5 (0.77) | GRM5HPGD | |
| SCHEMBL990813 | 0.85 | GRM5 (1.00) | GRM5HPGD | |
| SCHEMBL990910 | 0.85 | GRM5 (1.00) | GRM5HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | claimed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885NPC1 1500/4885MAPT 548/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GRM5 680/4885NPC1 437/4885MAPT 884/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885NPC1 1500/4885MAPT 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.